Dr. Joshua Lukenbill

About Joshua Lukenbill

Education:

• Earned dual BS degrees in biochemistry and psychology from The University of Iowa.
• Attended medical school at A.T. Still University, Kirksville, MO.
• Completed an Internal Medicine residency and Hematology/Oncology fellowship at The Cleveland Clinic.

Experience:

• Board Certified in Oncology, Hematology, and Internal Medicine.
• Joined Mission in 2017 and is currently practicing in Des Moines, IA.
• Holds roles in research and education with affiliations to Iowa Methodist Medical Center, University of Iowa, and Des Moines University.
• Active member of the American Society of Hematology and American Society of Clinical Oncology.

Area of expertise

Affiliated Hospitals

Medical Oncology And Hematology Associates-Des Moines

Iowa Methodist Medical Center

Clinical Trials Joshua Lukenbill is currently running

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Recruiting2 awards Phase 32 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting2 awards Phase 319 criteria

More about Joshua Lukenbill

Other Doctors you might be interested in

Frequently asked questions